ERBB2 and cancer: At a pre-clinical level, this synergistic relationship appears to be due to the heterodimerization of RANK and HER2 receptors on cancer cells, as well as through interactions in their downstream signalling pathways, and perhaps prevents the development of resistance to HER2-directed therapy.